Diabetes Care:胰岛素抵抗或始于儿童期

2012-02-06 MedSci MedSci原创

 英国一项长达9年的纵向前瞻性队列研究(The EarlyBird Diabetes study,EarlyBird 26)证实,胰岛素抵抗(IR)在儿童中期,即在青春期开始之前的几年时间内即开始产生。IR与儿童年龄的相关性超过进入青春期。超过60%的青春期前IR变异无法解释。鉴于儿童期糖尿病的人口统计数据正在发生变化,青春期前的IR可能是重要原因。研究在2

 英国一项长达9年的纵向前瞻性队列研究(The EarlyBird Diabetes study,EarlyBird 26)证实,胰岛素抵抗(IR)在儿童中期,即在青春期开始之前的几年时间内即开始产生。IR与儿童年龄的相关性超过进入青春期。超过60%的青春期前IR变异无法解释。鉴于儿童期糖尿病的人口统计数据正在发生变化,青春期前的IR可能是重要原因。研究在2012年1月25日在线发表于《糖尿病护理》(Diabetes Care)杂志。

  胰岛素抵抗与糖尿病相关。男女青春期IR水平较高,有研究显示这一增加独立于肥胖的变化。然而,较少的纵向研究关注儿童,同时IR是否归因于青春期真正开始目前尚不清楚。该研究以5~14岁的健康儿童为研究对象,旨在获取IR和青春期开始相关性的纵向研究数据,及其与年龄、性别、肥胖和胰岛素样生长因子(IGF – 1)之间的相互作用。

  研究共纳入235例儿童(134例为男生)受试者,每年对受试者的稳态模型评估(HOMA - IR),皮脂(SSF),肥胖(脂肪的百分比,采用双能X线骨密度仪测量),血清瘦素和IGF – 1水平进行测量。青春期的起始采用坦纳氏期(TS)以及促黄体生成素(LH)能够连续检测(≥0.2 国际单位/升)的年龄进行界定。

  结果表明,IR自7岁开始日见增多,即达到TS2或LH可检测年龄之前的3~4年。在进入青春期前的3年内,肥胖和IGF – 1水平的增加可以共同解释34%男孩和35%女孩的IR变异(P值均<0.001)。IGF–1对男孩IR的影响更为显著,尽管其IGF-1的水平相对较低。

  链接:

  Age Before Stage: Insulin Resistance Rises Before the Onset of Puberty

  A 9-year longitudinal study (Early Bird 26)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1749323, encodeId=fc471e4932365, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Jun 07 04:14:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759110, encodeId=defe1e591109f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu May 10 10:14:00 CST 2012, time=2012-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636470, encodeId=cb6516364e01e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 26 10:14:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900922, encodeId=e3a219009228f, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Aug 17 03:14:00 CST 2012, time=2012-08-17, status=1, ipAttribution=)]
    2012-06-07 baoya
  2. [GetPortalCommentsPageByObjectIdResponse(id=1749323, encodeId=fc471e4932365, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Jun 07 04:14:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759110, encodeId=defe1e591109f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu May 10 10:14:00 CST 2012, time=2012-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636470, encodeId=cb6516364e01e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 26 10:14:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900922, encodeId=e3a219009228f, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Aug 17 03:14:00 CST 2012, time=2012-08-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1749323, encodeId=fc471e4932365, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Jun 07 04:14:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759110, encodeId=defe1e591109f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu May 10 10:14:00 CST 2012, time=2012-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636470, encodeId=cb6516364e01e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 26 10:14:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900922, encodeId=e3a219009228f, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Aug 17 03:14:00 CST 2012, time=2012-08-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1749323, encodeId=fc471e4932365, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Jun 07 04:14:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759110, encodeId=defe1e591109f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu May 10 10:14:00 CST 2012, time=2012-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636470, encodeId=cb6516364e01e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 26 10:14:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900922, encodeId=e3a219009228f, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Aug 17 03:14:00 CST 2012, time=2012-08-17, status=1, ipAttribution=)]

相关资讯

J Hepatol:胰岛素抵抗(IR)降低丙肝持续病毒学应答率

 《肝脏病学杂志》[J Hepatol 2011,55(6):1187]发表法国一项荟萃分析:与没有胰岛素抵抗(IR)的患者相比,慢性丙型肝炎伴IR的患者应用聚乙二醇干扰素加利巴韦林治疗后持续病毒学应答率低20%,基线时稳态模型评估法-IR指数是SVR的一个重要决定因素。 原始文献: Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, M

高度胰岛素抵抗可能与缺血性卒中溶栓后转归不佳相关

 西班牙学者的一项研究表明,在急性缺血性卒中行溶栓治疗后,高度胰岛素抵抗(IR)可能与更为持续的动脉闭塞和更差的远期转归相关。论文于2011年9月12日在线发表于《糖尿病护理》(Diabetes Care)。   此项前瞻性、观察性、纵向研究序贯性入组急性缺血性卒中患者,受试者均伴有大脑中动脉(MCA)阻塞并且接受了静脉溶栓治疗。接受胰岛素治疗的急性高血糖患者(≥155 mg